KR100347287B1 - 콜레시스토키닌또는가스트린의길항물질로서유용한1,5-벤조디아제핀유도체 - Google Patents

콜레시스토키닌또는가스트린의길항물질로서유용한1,5-벤조디아제핀유도체 Download PDF

Info

Publication number
KR100347287B1
KR100347287B1 KR1019960700279A KR19960700279A KR100347287B1 KR 100347287 B1 KR100347287 B1 KR 100347287B1 KR 1019960700279 A KR1019960700279 A KR 1019960700279A KR 19960700279 A KR19960700279 A KR 19960700279A KR 100347287 B1 KR100347287 B1 KR 100347287B1
Authority
KR
South Korea
Prior art keywords
group
ethyl
tetrahydro
alkyl
benzodiazepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019960700279A
Other languages
English (en)
Korean (ko)
Inventor
다니엘 도나티
안토넬라 우르시니
마우로 코르시
Original Assignee
글락소 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소 에스.피.에이. filed Critical 글락소 에스.피.에이.
Application granted granted Critical
Publication of KR100347287B1 publication Critical patent/KR100347287B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1019960700279A 1993-07-20 1994-07-18 콜레시스토키닌또는가스트린의길항물질로서유용한1,5-벤조디아제핀유도체 Expired - Fee Related KR100347287B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939314981A GB9314981D0 (en) 1993-07-20 1993-07-20 Chemical compounds
GB9314981.3 1993-07-20
PCT/EP1994/002353 WO1995003285A1 (en) 1993-07-20 1994-07-18 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists

Publications (1)

Publication Number Publication Date
KR100347287B1 true KR100347287B1 (ko) 2002-12-06

Family

ID=10739096

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960700279A Expired - Fee Related KR100347287B1 (ko) 1993-07-20 1994-07-18 콜레시스토키닌또는가스트린의길항물질로서유용한1,5-벤조디아제핀유도체

Country Status (32)

Country Link
US (1) US5716953A (https=)
EP (1) EP0710230B1 (https=)
JP (1) JP3587849B2 (https=)
KR (1) KR100347287B1 (https=)
CN (1) CN1050835C (https=)
AP (1) AP492A (https=)
AT (1) ATE171167T1 (https=)
AU (1) AU687858B2 (https=)
CA (1) CA2167308A1 (https=)
CO (1) CO4290299A1 (https=)
CZ (1) CZ290472B6 (https=)
DE (1) DE69413405T2 (https=)
DK (1) DK0710230T3 (https=)
EC (1) ECSP941120A (https=)
ES (1) ES2123812T3 (https=)
FI (1) FI960223A7 (https=)
GB (1) GB9314981D0 (https=)
HR (1) HRP940411B1 (https=)
HU (1) HU222439B1 (https=)
IL (1) IL110366A (https=)
IS (1) IS4190A (https=)
MY (1) MY118638A (https=)
NO (1) NO313288B1 (https=)
NZ (1) NZ271075A (https=)
PE (1) PE8295A1 (https=)
PL (1) PL175609B1 (https=)
RU (1) RU2135485C1 (https=)
SI (1) SI0710230T1 (https=)
SV (1) SV1994000031A (https=)
TW (1) TW290542B (https=)
WO (1) WO1995003285A1 (https=)
ZA (1) ZA945238B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
PE27497A1 (es) * 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
AU3459497A (en) * 1996-07-12 1998-02-09 Chugai Seiyaku Kabushiki Kaisha Cancer cell proliferation inhibitors
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6569851B1 (en) * 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
ATE261945T1 (de) 1999-10-15 2004-04-15 Hoffmann La Roche Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
US20050192265A1 (en) * 2003-03-20 2005-09-01 Thompson Richard C. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
SI1673347T1 (sl) * 2003-10-06 2015-10-30 F. Hoffmann - La Roche Ag Substituirani derivati dibenzo-azepina in benzo-diazepina, ki so uporabni kot inhibitorji gama-sekretaze
US8128692B2 (en) * 2004-02-27 2012-03-06 Aortx, Inc. Prosthetic heart valves, scaffolding structures, and systems and methods for implantation of same
ES2369866T3 (es) * 2007-04-19 2011-12-07 F. Hoffmann-La Roche Ag Derivados de dihidro-benzo[b][1,4]diazepin-2-ona-sulfonamida.
RU2540464C2 (ru) * 2012-05-28 2015-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Водорастворимое производное амида салициловой кислоты, обладающее транквилизирующей, ноотропной и анальгезирующей активностью
CN103435562B (zh) * 2013-08-26 2016-02-24 华东理工大学 6-取代苯并二氮卓-2,4-二酮类化合物及其用途
RU2702359C1 (ru) * 2019-06-04 2019-10-08 Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук Способ получения 2,2,4-триалкил-2,3-дигидро-1Н-1,5-бензодиазепинов

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2103745A1 (de) * 1971-01-27 1972-08-10 CH. Boehringer Sohn, 6507 Ingelheim Neue 5-AryJ-(bzw. Heteroaryl)-3-hydroxylH-l,5-benzodiazepin-2,4-(3H,5H)-dioneund Verfahren zu ihrer Herstellung
FR2641280B1 (fr) * 1988-12-29 1994-01-21 Roussel Uclaf Nouveaux derives de la 2,4-dioxo 2,3,4,5-tetrahydro 1h-1,5-benzodiazepine, leur procede de preparation et leur application comme medicaments
CA2068355A1 (en) * 1991-05-14 1992-11-15 Mark S. Chambers Benzodiazephine derivatives, compositions containing them and their use in therapy
GB9201181D0 (en) * 1992-01-21 1992-03-11 Glaxo Spa Chemical compounds
GB9201180D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
GB9225492D0 (en) * 1992-12-05 1993-01-27 Glaxo Group Ltd Amine derivatives

Also Published As

Publication number Publication date
IS4190A (is) 1995-01-21
IL110366A (en) 1999-01-26
SV1994000031A (es) 1995-10-04
EP0710230B1 (en) 1998-09-16
US5716953A (en) 1998-02-10
TW290542B (https=) 1996-11-11
AP492A (en) 1996-05-13
RU2135485C1 (ru) 1999-08-27
FI960223A0 (fi) 1996-01-17
NO313288B1 (no) 2002-09-09
AP9400657A0 (en) 1994-07-31
PE8295A1 (es) 1995-04-20
PL312659A1 (en) 1996-04-29
JPH09502428A (ja) 1997-03-11
CA2167308A1 (en) 1995-02-02
PL175609B1 (pl) 1999-01-29
CZ290472B6 (cs) 2002-07-17
NO960237L (no) 1996-03-19
ECSP941120A (es) 1995-01-16
ES2123812T3 (es) 1999-01-16
EP0710230A1 (en) 1996-05-08
WO1995003285A1 (en) 1995-02-02
CZ17396A3 (en) 1996-07-17
AU7458994A (en) 1995-02-20
MY118638A (en) 2004-12-31
SI0710230T1 (en) 1999-02-28
DE69413405T2 (de) 1999-04-15
ZA945238B (en) 1995-02-09
HUT73499A (en) 1996-08-28
CN1050835C (zh) 2000-03-29
DE69413405D1 (de) 1998-10-22
FI960223A7 (fi) 1996-03-19
NO960237D0 (no) 1996-01-19
HU222439B1 (hu) 2003-07-28
IL110366A0 (en) 1994-10-21
ATE171167T1 (de) 1998-10-15
HRP940411B1 (en) 2000-12-31
CN1138853A (zh) 1996-12-25
DK0710230T3 (da) 1999-06-14
HRP940411A2 (en) 1997-04-30
JP3587849B2 (ja) 2004-11-10
GB9314981D0 (en) 1993-09-01
HU9600124D0 (en) 1996-03-28
AU687858B2 (en) 1998-03-05
CO4290299A1 (es) 1996-04-17
NZ271075A (en) 1998-06-26

Similar Documents

Publication Publication Date Title
KR100347287B1 (ko) 콜레시스토키닌또는가스트린의길항물질로서유용한1,5-벤조디아제핀유도체
KR100364948B1 (ko) 콜레시스토키닌길항활성또는작용활성을갖는1,5-벤조디아제핀유도체
FI111632B (fi) Menetelmä CCK-B-antagonistisesti vaikuttavien 1,5-bentsodiatsepiinijohdannaisten valmistamiseksi
US5618812A (en) Benzodiazepine derivatives
EP0672037B1 (en) 1,4-benzodiazepine derivatives and their use as cck-modulators
US5451582A (en) Benzodiazepine derivatives, compositions containing them and their use in therapy
US5302591A (en) Benzodiazepine derivatives
AU667690B2 (en) Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors
US5686449A (en) 1,5-benzodiazepines useful as gastrinor CCK-antagonists
AU688316B2 (en) 1,5 benzodiazepine derivatives having CCK and/or gastrin antagonistic activity
GB2290788A (en) Benzazepine CCK and gastrin antagonists
US5641775A (en) 3-phenylureido-1,5-benzodiazepine-diones useful as gastrin or antagonists
HRP940330A2 (en) Amine derivatives
GB2266528A (en) Benzodiazepine derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20050723

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20050723

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000